Fibrocytes: Potential new therapeutic targets for pulmonary hypertension?

European Respiratory Journal

Volumn 36, Issue 6, 2010, Pages 1232-1235

  Stenmark, K R ^a   Frid, M G ^a   Yeager, M E ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; CD11 ANTIGEN; CD14 ANTIGEN; CD34 ANTIBODY; CD45 ANTIGEN; CHEMOKINE RECEPTOR CCR7; CHEMOKINE RECEPTOR CXCR4; COLLAGEN TYPE 1; COLLAGEN TYPE 3; CYCLIC AMP; EOTAXIN; GAMMA INTERFERON; GELATINASE A; GELATINASE B; I KAPPA B; INTERLEUKIN 10; INTERLEUKIN 12P70; INTERLEUKIN 13; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MAMMALIAN TARGET OF RAPAMYCIN; MONOCYTE CHEMOTACTIC PROTEIN 1; PROSTACYCLIN; THYMUS AND ACTIVATION REGULATED CHEMOKINE; TUMOR NECROSIS FACTOR; VIMENTIN;

ARTERY INTIMA PROLIFERATION; BLOOD VESSEL INJURY; BONE MARROW CELL; CELL; CELL HYPOXIA; CELL STRUCTURE; CELL TRANSFORMATION; CONNECTIVE TISSUE CELL; EDITORIAL; FIBROCYTE; FIBROSIS; INFLAMMATORY CELL; LUNG ARTERY; MESENCHYME CELL; MICROENVIRONMENT; MONOCYTE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PULMONARY HYPERTENSION; SCIENTIFIC LITERATURE; STEM CELL; TARGET CELL; TH2 CELL; WOUND HEALING;

ANIMALS; CYTOKINES; EPOPROSTENOL; FIBROBLASTS; HUMANS; HYPERTENSION, PULMONARY; MESENCHYMAL STEM CELLS; MICE; RATS;

EID: 78649735320     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00137410     Document Type: Editorial

References (50)

1. Humbert M, Sitbon O, Chaouat A, et al. Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation 2010; 122: 156-163.
2. Humbert M, Sitbon O, Yaïci A, et al. Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension. Eur Respir J 2010; 36: 549-555.
3. Morrell NW, Adnot S, Archer SL, et al. Cellular and molecular basis of pulmonary arterial hypertension. J Am Coll Cardiol 2009; 54: Suppl. S20-S31.
4. Humbert M, Morrell NW, Archer SL, et al. Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol 2004; 43: Suppl. S, 13S-24S.
5. Majka SM, Skokan M, Wheeler L, et al. Evidence for cell fusion is absent in vascular lesions associated with pulmonary arterial hypertension. Am J Physiol 2008; 295: L1028-L1039.
6. Pietra GG, Capron F, Stewart S, et al. Pathologic assessment of vasculopathies in pulmonary hypertension. J Am Coll Cardi 2004; 43: Suppl. S, 25S-32S.
7. Yi ES, Kim H, Ahn H, et al. Distribution of obstructive intimal lesions and their cellular phenotypes in chronic pulmonary hypertension. A morphometric and immunohistochemical study. Am J Respir Crit Care Med 2000; 162: 1577-1586.
8. Iwata H, Sata M. Potential contribution of bone marrow-derived precursors to vascular repair and lesion formation: lessons from animal models of vascular diseases. Front Biosci 2007; 12: 4157-4167.
9. Tanaka K, Sata M. Contribution of circulating vascular progenitors in lesion formation and vascular healing: lessons from animal models. Current Opin Lipidol 2008; 19: 498-504.
10. Bellini A, Mattoli S. The role of the fibrocyte, a bone marrow-derived mesenchymal progenitor, in reactive and reparative fibroses. Lab Invest 2007; 87: 858-870.
11. Bucala R, Spiegel LA, Chesney J, et al. Circulating fibrocytes define a new leukocyte subpopulation that mediates tissue repair. Mol Med 1994; 1: 71-81.
12. Herzog EL, Bucala R. Fibrocytes in health and disease. Exp Hematol 2010; 38: 548-556.
13. Pilling D, Fan T, Huang D, et al. Identification of markers that distinguish monocyte-derived fibrocytes from monocytes, macrophages, and fibroblasts. PLoS One 2009; 4: e7475.
14. Abe R, Donnelly SC, Peng T, et al. Peripheral blood fibrocytes: differentiation pathway and migration to wound sites. J Immunol 2001; 166: 7556-7562.
15. Schmidt M, Sun G, Stacey MA, et al. Identification of circulating fibrocytes as precursors of bronchial myofibroblasts in asthma. J Immunol 2003; 171: 380-389.
16. Hartlapp I, Abe R, Saeed RW, et al. Fibrocytes induce an angiogenic phenotype in cultured endothelial cells and promote angiogenesis in vivo. FASEB J 2001; 15: 2215-2224.
17. Gomperts BN, Strieter RM. Fibrocytes in lung disease. J Leukoc Biol 2007; 82: 449-456.
18. Phillips RJ, Burdick MD, Hong K, et al. Circulating fibrocytes traffic to the lungs in response to CXCL12 and mediate fibrosis. J Clin Invest 2004; 114: 438-446.
19. Chesney J, Metz C, Stavitsky AB, et al. Regulated production of type I collagen and inflammatory cytokines by peripheral blood fibrocytes. J Immunol 1998; 160: 419-425.
20. Medbury H. Role of fibrocytes in atherogenesis. In: Bucala R, ed. Fibrocytes: New Insights into Tissue Repair and Systemic Fibroses. Singapore, World Scientific Publishing Co., 2007; pp. 175-194.
21. Medbury HJ, Tarran SL, Guiffre AK, et al. Monocytes contribute to the atherosclerotic cap by transformation into fibrocytes. Int Angiol 2008; 27: 114-123.
22. Tacke F, Randolph GJ. Migratory fate and differentiation of blood monocyte subsets. Immunobiology 2006; 211: 609-618.
23. Varcoe RL, Mikhail M, Guiffre AK, et al. The role of the fibrocyte in intimal hyperplasia. J Thromb Haemost 2006; 4: 1125-1133.
24. Hillebrands JL, Onuta G, Rozing J. Role of progenitor cells in transplant arteriosclerosis. Trends Cardiovasc Med 2005; 15: 1-8.
25. Onuta G, van Ark J, Rienstra H, et al. Development of transplant vasculopathy in aortic allografts correlates with neointimal smooth muscle cell proliferative capacity and fibrocyte frequency. Atherosclerosis 2010; 209: 393-402.
26. Sugiyama S, Kugiyama K, Nakamura S, et al. Characterization of smooth muscle-like cells in circulating human peripheral blood. Atherosclerosis 2006; 187: 351-362.
27. Hillebrands JL, Klatter FA, van den Hurk BM, et al. Origin of neointimal endothelium and α-actin-positive smooth muscle cells in transplant arteriosclerosis. J Clin Invest 2001; 107: 1411-1422.
28. McDermott DH, Yang Q, Kathiresan S, et al. CCL2 polymorphisms are associated with serum monocyte chemoattractant protein-1 levels and myocardial infarction in the Framingham Heart Study. Circulation 2005; 112: 1113-1120.
29. Frid MG, Brunetti JA, Burke DL, et al. Hypoxia-induced pulmonary vascular remodeling requires recruitment of circulating mesenchymal precursors of a monocyte/macrophage lineage. Am J Pathol 2006; 168: 659-669.
30. Burke DL, Frid MG, Kunrath CL, et al. Sustained hypoxia promotes the development of a pulmonary artery-specific chronic inflammatory microenvironment. Am J Physiol 2009; 297: L238-L250.
31. Nikam VS, Schermuly RT, Dumitrascu R, et al. Treprostinil inhibits the recruitment of bone marrow-derived circulating fibrocytes in chronic hypoxic pulmonary hypertension. Eur Respir J 2010; 36: 1302-1314.
32. Hayashida K, Fujita J, Miyake Y, et al. Bone marrow-derived cells contribute to pulmonary vascular remodeling in hypoxia-induced pulmonary hypertension. Chest 2005; 127: 1793-1798.
33. Davie NJ, Crossno JT Jr, Frid MG, et al. Hypoxia-induced pulmonary artery adventitial remodeling and neovascularization: contribution of progenitor cells. Am J Physiol 2004; 286: L668-L678.
34. Young KC, Torres E, Hatzistergos KE, et al. Inhibition of the SDF-1/CXCR4 axis attenuates neonatal hypoxia-induced pulmonary hypertension. Circ Res 2009; 104: 1293-1301.
35. Sakai N, Wada T, Yokoyama H, et al. Secondary lymphoid tissue chemokine (SLC/CCL21)/CCR7 signaling regulates fibrocytes in renal fibrosis. Proc Natl Acad Sci USA 2006; 103: 14098-14103.
36. Schnoor M, Cullen P, Lorkowski J, et al. Production of type VI collagen by human macrophages: a new dimension in macrophage functional heterogeneity. J Immunol 2008; 180: 5707-5719.
37. Gomberg-Maitland M, Olschewski H. Prostacyclin therapies for the treatment of pulmonary arterial hypertension. Eur Respir J 2008; 31: 891-901.
38. Badesch DB, Tapson VF, McGoon MD, et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med 2000; 132: 425-434.
39. Idzko M, Hammad H, van Nimwegen M, et al. Inhaled iloprost suppresses the cardinal features of asthma via inhibition of airway dendritic cell function. J Clin Invest 2007; 117: 464-472.
40. 2-IP signaling blocks allergic pulmonary inflammation by preventing recruitment of CD4+ Th2 cells into the airways in a mouse model of asthma. J Immunol 2007; 179: 6193-6203.
41. Jaffar Z, Wan KS, Roberts K. A key role for prostaglandin I2 in limiting lung mucosal Th2, but not Th1, responses to inhaled allergen. J Immunol 2002; 169: 5997-6004.
42. Zhou W, Hashimoto K, Goleniewska K, et al. Prostaglandin I2 analogs inhibit proinflammatory cytokine production and T cell stimulatory function of dendritic cells. J Immunol 2007; 178: 702-710. (Pubitemid 46095142)
43. Zhou W, Blackwell TS, Goleniewska K, et al. Prostaglandin I2 analogs inhibit Th1 and Th2 effector cytokine production by CD4 T cells. J Leukoc Biol 2007; 81: 809-817.
44. Raychaudhuri B, Malur A, Bonfield TL, et al. The prostacyclin analogue treprostinil blocks NFkB nuclear translocation in human alveolar macrophages. J Biol Chem 2002; 277: 33344-33348.
45. Goya K, Otsuki M, Xu X, et al. Effects of the prostaglandin I2 analogue, beraprost sodium, on vascular cell adhesion molecule-1 expression in human vascular endothelial cells and circulating vascular cell adhesion molecule-1 level in patients with type 2 diabetes mellitus. Metabolism 2003; 52: 192-198.
46. Katsushi H, Kazufumi N, Hideki F, et al. Epoprostenol therapy decreases elevated circulating levels of monocyte chemoattractant protein-1 in patients with primary pulmonary hypertension. Circ J 2004; 68: 227-231.
47. Strassheim D, Riddle SR, Burke DL, et al. Prostacyclin inhibits IFN-γ-stimulated cytokine expression by reduced recruitment of CBP/p300 to STAT1 in a SOCS-1-independent manner. J Immunol 2009; 183: 6981-6988.
48. Shao DD, Suresh R, Vakil V, et al. Pivotal advance: Th-1 cytokines inhibit, and Th-2 cytokines promote fibrocyte differentiation. J Leukoc Biol 2008; 83: 1323-1333.
49. Mehrad B, Burdick MD, Strieter RM. Fibrocyte CXCR4 regulation as a therapeutic target in pulmonary fibrosis. Int J Biochem Cell Biol 2009; 41: 1708-1718.
50. Sakai N, Wada T, Matsushima K, et al. The renin-angiotensin system contributes to renal fibrosis through regulation of fibrocytes. J Hypertens 2008; 26: 780-790.